MedTrace Logo

The Effect of ENZAlutamide on the Anti-Xa Levels of Patients Receiving DOACs

NCT03920566 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2019-04-22

No results posted yet for this study

Summary

This study aims to determine the nature and significance of the theoretical drug interaction between enzalutamide (a drug used to treat prostate cancer) and the direct-acting oral anticoagulant drugs (DOACs). This will be done in two ways: a laboratory study which will take place at the University of Brighton, and a clinical study in which patients will be identified who are currently taking DOACs and are due to start treatment with enzalutamide. The activity of the DOAC will be monitored using anti-Xa levels before and after commencing treatment with enzalutamide.

Conditions

  • Drug Interaction

Interventions

OTHER

Anti-Xa level

Anti-Xa level taken before commencing enzalutamide and repeated after 4 weeks of treatment

Sponsors & Collaborators

  • Pharmacy Research UK

    collaborator UNKNOWN

  • University of Brighton

    collaborator OTHER

  • Royal Marsden NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Emma Foreman · Royal Marsden NHS Foundation Trust

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-31
Primary Completion
2020-04-30
Completion
2020-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03920566 on ClinicalTrials.gov